Hormone Therapy May Aid GLP-1 Weight Loss in Women

A study suggests women taking GLP-1 drugs could see enhanced weight loss results when using menopause hormone therapy.

Updated on Oct. 21, 2026 in Weight Loss

Isometric editorial illustration of a glass beaker containing a stylized molecular structure, representing medical research on hormone and weight-loss therapies. — A new study indicates that menopause hormone therapy may enhance weight loss efficacy for women using GLP-1 medications. AI Illustration. Upload story photo >

Live Poll

Would you discuss menopause hormone therapy with your doctor to potentially improve weight loss results?

A study of 3,900 women shows that combining menopause hormone therapy with GLP-1 medications may enhance weight loss. These findings, which affect the 1 in 5 women aged 50 to 64 who use these drugs, will be presented on October 22, 2026.

Why it matters

Understanding how hormone therapy interacts with weight loss medications is critical for the growing number of menopausal women managing both conditions. The results suggest that these treatments might have a synergistic effect, potentially improving outcomes for women seeking effective weight management.

This retrospective study of 3,900 women aged 45 and older compared weight loss outcomes between patients on hormone therapy and those without. Participants using semaglutide saw an 11% average weight loss with hormone therapy compared to 9.5% without, though these preliminary findings are not yet confirmed by prospective trials.

The players

The Menopause Society

A professional organization dedicated to advancing the health and quality of life of women during menopause and beyond through scientific research.

The details

Researchers observed that 22% of women combining semaglutide with hormone therapy achieved at least 20% total body weight loss, compared to 18% of those on semaglutide alone. For tirzepatide users, those on hormone therapy reached 6.6% weight loss at three months, slightly higher than the 5.9% seen in the control group. Preclinical data suggests a potential synergistic effect where estrogen influences GLP-1 signaling pathways, which may help drive these increased metabolic benefits.

October 22, 2026: Research presentation at the Menopause Society meeting.
Through October 24, 2026: Menopause Society annual meeting in San Diego.

Health Landscape

This research sits within the ongoing clinical dialogue at the Menopause Society annual meeting regarding the management of metabolic health during midlife. It contributes to the evolving understanding of how hormonal interventions may complement modern pharmacotherapy for weight loss.

Women navigating weight management and menopause symptoms should consider these preliminary findings as a topic for their next clinical appointment. It is worth discussing with your doctor how your current medication regimen fits into your broader goals, given that these results are still being verified.

The takeaway

Preliminary evidence suggests that menopause hormone therapy may improve weight loss results for women taking GLP-1 medications. If you are managing both, keep track of your progress and bring your questions regarding medication combinations to your next primary care visit.